Icecure Medical Ltd. · NASDAQ:ICCM
Icecure Medical — Investor Presentation (July 2022)
27 slides from Icecure Medical's investor presentation, July 2022
Slide 1: Freezing cancer in its tracks
Freezing cancer in its tracks IceCure Medical enabling non‐surgical, treatment of cancerous tumors Corporate Presentation | July 2022 (NASDAQ & TASE: ICCM) icecure-medical.com Nasdaq & TASE: ICCM
Slide 2: Forward Looking Statement
Forward Looking Statement Disclaimer: IMPORTANT: The following applies to this document, the oral presentation of the information in this document by IceCure Medical Ltd. (the “Company”, “we” or “us”) and any question-and- answer session that will follow the oral presentation (collectively, the “Pre
Slide 3: Introducing ProSense Non-surgical Next-Generation Cryoablation Technology
Introducing ProSense® Non-surgical Next-Generation Cryoablation Technology Cryoablation is a minimally invasive image guided (US or CT) treatment that uses extreme cold to freeze and accurately destroy diseased tissue within the tumor zone IceCure’s flagship product ProSense® cryoablates tumors quic
Slide 4: Company Highlights
Company Highlights ICE3 Breast Cancer Trial Regulatory Wide market in US for FDA approval in approval in 14* Growing number of applications treating early-stage countries global distribution $2.4 B tumor ablation including U.S. and agreements market breast tumors Europe by 2028 † Collaboration with
Slide 5: Market Opportunities
Market Opportunities Tumor Ablation US Cryoablation Tumor Ablation Market Expected To Reach Breast Tumors $2.4 Billion in 2028† ~340K new breast cancer patients estimated in 2022* 10% of female pop. est. to have fibroadenomas** $2.4B (CAGR) Potential driven Breast Cancer Breast Fibroadenoma by non/m
Slide 6: Regulatory approvals worldwide
Regulatory approvals worldwide FDA Approval for general CE Approval for benign or Rest of World Approvals: Israel, Singapore, Hong-Kong, India, minimally-invasive cryoablation malignant tissue of: Thailand, Australia, South Africa, China applications, specific indications Breast, Lung, Musculoskelet
Slide 7: Clinical evidence
Clinical evidence Kidney cancer: Breast cancer: Israel ICE Secret Trial, 120 cases ICE3 Trial Initial results reported ** 98% recurrence free in the ICE3 trial as of April 2021 in small, low-risk, early-stage malignant breast tumors (190 out of the 45 small kidney masses (≤ 4cm) treated 194 eligible
Slide 8: ProSense is Superior to Competing Thermal Ablation Technologies
ProSense is Superior to Competing Thermal Ablation Technologies Cryoablation Thermal Ablation IceCure ProSense® (Radiofrequency & Microwave) Pain Minimal to no pain* Very painful Anesthesia Local High amount to general Excellent contour under Visualization Limited visualization Ultrasound & CT Accur
Slide 9: ProSense - Advanced Cryoablation Technology
ProSense® - Advanced Cryoablation Technology Superior Liquid Nitrogen (LN2) technology for optimal tumor destruction* 40 Rapid cooling Temperature (ºc) 20 IceCure system 0 Argon system Lower and more -20 Other LN2 systems stable temperatures -40 -60 Larger lethal zone -80 -100 LN2 less expensive -12
Slide 10: Breast Tumor Market Activities
Breast Tumor Market Activities Nasdaq & TASE: ICCM 10
Slide 11: Challenges in Breast Cancer Surgery (Lumpectomy)
Challenges in Breast Cancer Surgery (Lumpectomy) • Cost • Cosmetic outcome • 14% - 20% of patients undergo re-excision after lumpectomy due to unclear margins* • Recovery time • Use of operating rooms places an additional strain on hospital resources * https://link.springer.com/article/10.1245/s1043
Slide 12: ProSense - Value for All
ProSense® - Value for All Patient Physician Insurer Healthcare Provider LN2* - Maximum Efficacy Easy to Use, In-office Lower Reimbursement Patient Demand Drives Procedure Expense Vs. Surgery Reimbursement Non-surgical Low Risk, Safe Procedure In-Office Procedure Faster, In-Office Pro
Slide 13: ICE3: Landmark U.S. Breast Cancer Trial
Unique Value Proposition ICE3: Landmark U.S. Breast Cancer Trial Largest USA controlled multicenter clinical trial ever performed for LN2 based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery “Cryoablation potentially represents a dramatic improvemen
Slide 14: ICE3: U.S. Breast Cancer Trial Delivers Interim Results
ICE3: U.S. Breast Cancer Trial Delivers Interim Results 194 19 82 Patients Eligible Hospitals Patients Followed For 5 Years* Patients (Incl. Columbia University Medical Center and Mount Sinai *By June 2022 Beth Israel) 97.94% 100% 98% 95% Results Recurrence free Safe procedure Doctor satisfaction Pa
Slide 15: Breast Cancer & Benign Tumors U.S. Strategy
Breast Cancer & Benign Tumors U.S. Strategy Regulatory Strategy FDA clearance for general minimally-invasive cryoablation applications FDA clearance for fibroadenoma (benign breast tumors) cryoablation Completed ICE3 study enrollment, promising interim results presented at the 2021 ASBrS Annua
Slide 16: Breast Cancer - China Strategy
Breast Cancer - China Strategy Regulatory strategy Console approved by the National Medical Products Administration (NMPA) Shanghai Medtronic Initiated a registration process for the disposable probes, estimated Zhikang Medical Devices Co. Ltd end of 2022 Approved in Hong Kong Go to market S
Slide 17: Breast Cancer - Japan Terumo Agreement
Breast Cancer - Japan Terumo Agreement Exclusive strategic distribution agreement with Terumo to accelerate commercialization of ProSense® in Japan, Singapore, and Thailand For >6 years ProSense® has been sold through a Private Import License—now leveraging agreement with Terumo to expand distributi
Slide 18: Fibroadenomas
FIBROADENOMAS Nasdaq & TASE: ICCM 18
Slide 19: ProSense: Becoming the Standard in Fibroadenoma Therapy
ProSense®: Becoming the Standard in Fibroadenoma Therapy Treating 60 patients fibroadenomas who underwent successfully office-based since treatment clinical trials reported: began in 2012 (ProSense® cryoablation treatment under ultrasound guidance) Minimally invasive, in-office Lesions tended to alt
Slide 20: Interventional Radiology
Interventional Radiology Kidney Lung Bone Liver Cancer Cancer Cancer Cancer Nasdaq Nasdaq & TASE: & TASE: ICCM ICCM 20
Slide 21: Interventional Radiology: Expanding Product Line
Interventional Radiology: Expanding Product Line Over 500,000 new people each year are diagnosed with kidney, lung, liver and prostate cancer in the U.S. alone >2.5M new cases of lung 488K new cases of kidney Pain care for bone cancer cancer globally by 2025* cancer globally by 2025* metastasis • Ja
Slide 22: Interventional Radiology - USA Strategy
Interventional Radiology - USA Strategy Regulatory Strategy FDA approval for general minimally-invasive cryoablation applications FDA approval for kidney and liver as of Dec 2019 FDA granted ProSense® Breakthrough Devices Designation for proposed indications, including for use in the treatment
Slide 23: Business Model – Revenue Generators
Business Model – Revenue Generators Console and consumable probe business model Direct sales and via distributors Direct sales to hospitals, clinics and doctor offices Reselling to distributors Used as a mobile device in different hospitals, clinics, doctor offices in Europe Console related re
Slide 24: Well-Financed to Advance Commercialization of ProSense
Well-Financed to Advance Commercialization of ProSense® Cash (3/31/22)* $22.4 M Revenues (YE 12/31/21)* $4.1 M In 2021, raised $32M (gross) in private Price (6/13/22) $1.86 Market Cap (2/15/22) $66 M placement and Nasdaq offering led by Avg. Daily Trading Volume (3 months) 28 K three accredited inve
Slide 25: Global Presence of IceCure Technology
Global Presence of IceCure Technology NETHERLANDS POLAND HUNGARY GERMANY ROMANIA FRANCE SPAIN ITALY UNITED STATES JAPAN TURKEY CHINA ISRAEL INDIA TAIWAN HONG KONG COSTA RICA THAILAND SINGAPORE SOUTH AFRICA AUSTRALIA Nasdaq & TASE: ICCM 25
Slide 26: Proven Leadership Team
Proven Leadership Team Ron Mayron, Chairman of the Board Shay Levav, VP Clinical, Regulatory & QA Served for 20 years in several positions at Nearly 20 years’ experience in regulatory and quality Teva including as VP – Israel & Africa & assurance in the healthcare sector CEO of Teva Israel Eyal Sham
Slide 27: ProSense Freezing Cancer In Its Tracks
ProSense® Freezing Cancer In Its Tracks THANK YOU EYAL Shamir – CEO E: eyals@icecure-medical.com Ronen Tsimerman – CFO/COO E: ronent@icecure-medical.com T: +972-4-623-0333 Nasdaq & TASE: ICCM 27